Oncotelic Therapeutics, Inc. OTLC OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

22/100

0/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Oncotelic Therapeutics, Inc. (OTLC) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 20/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

22/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

25/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — OTLC

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.01

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$-0.54	$0.00	$-13.65M	-
2016	$-0.51	$0.00	$-13.65M	-
2017	$-0.52	$-100.00	$-13.81M	-
2018	$-0.07	$-100.00	$-2.74M	-
2019	$-0.12	$0.00	$-7.39M	-
2020	$-0.13	$1.74M	$-11.5M	-660.6%
2021	$-0.04	$0.00	$-11.39M	-
2022	$0.04	$0.00	$17.82M	-
2023	$-0.02	$70K	$-7.9M	-11290.1%
2024	$-0.01	$0.00	$-4.52B	-